Newsletter

Subscribe and receive updates on this company

Text STOCKS to 72727 for mobile alerts

We are excited to present Astellas Pharma, Inc. (OTC: ALPMF).

Full DD Report for ALPMF

You must become a subscriber to view this report.


Recent News from (OTC: ALPMF)

First Eagle Global Value Team Quarterly Commentary Q1 2018
Read more ...
Source: SeekingAlpha
Date: May, 03 2018 03:02
FDA accepts Pfizer's marketing application for expanded use of Xtandi
Pfizer (NYSE: PFE ) and collaboration partner Astellas Pharma ( OTCPK:ALPMF ) announce that the FDA has accepted under Priority Review the former's marketing application seeking approval for XTANDI (enzalutamide) for the treatment of men with non-metastatic castration-resistant prostate ca...
Source: SeekingAlpha
Date: March, 19 2018 16:38
Key events next week - healthcare
Noteworthy events for the week of Feb. 4 - 10 for healthcare investors: More news on: Protalix BioTherapeutics, Inc, Bristol-Myers Squibb Company, WellCare Health Plans, Inc., Healthcare stocks news, Read more ...
Source: SeekingAlpha
Date: February, 02 2018 09:37
3 Things In Biotech You Should Learn Today: January 25, 2018
Note: Subscribers to Avisol Capital Partners' Total Pharma Tracker got an early look at this publication. Consider becoming a subscriber today to get early access! Welcome to another edition of "3 Things In Biotech You Should Learn Today," a daily digest dedicated to helping you keep p...
Source: SeekingAlpha
Date: January, 26 2018 08:00
3 Things In Biotech You Should Learn Today: January 24, 2018
Note: Subscribers to Avisol Capital Partners Total Pharma Tracker got an early look at this publication. Welcome to another edition of "3 Things In Biotech You Should Learn Today," a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotec...
Source: SeekingAlpha
Date: January, 25 2018 08:30
Astellas Pharma's DNA vaccine candidate flunks late-stage study in CMV-positive HSCT patients; licensor Vical down 22% premarket
Astellas Pharma ( OTCPK:ALPMF ) and licensor Vical (NASDAQ: VICL ) announce that Astellas' investigational DNA vaccine candidate, Orphan Drug-tagged ASP0113, failed to achieve the primary endpoint and secondary endpoints in a Phase 3 clinical trial, HELIOS, in cytomegalovirus (CMV)-seropos...
Source: SeekingAlpha
Date: January, 22 2018 07:27
'Safer' Dividend Healthcare Gainers Glaxo, Pfizer & Medical Facilities Are Tagged Tops By Broker Targets For December
Actionable Conclusions (1-10): Brokers Calculated Top Ten Healthcare "Safer" Dividend Stocks to Net 0.56% to 23.2% Gains To December, 2018 Nine of ten top 'safer' dividend Healthcare dogs by yield (shaded in the chart above) were verified as being among the top ten gainers for the coming y...
Source: SeekingAlpha
Date: December, 29 2017 12:21
Astellas Pharma acquiring Mitobridge for $225M
Astellas Pharma ( OTCPK:ALPMF ) has exercised an option to acquire Mitobridge under terms of an existing R&D collaboration between the two. More news on: Astellas Pharma, Inc., Astellas Pharma, Inc. ADR, Healthcare stocks news, Merger & acquisition news, Read more ...
Source: SeekingAlpha
Date: November, 30 2017 19:28
3 Things In Biotech You Should Learn Today: November 21, 2017
Welcome to another edition of "3 Things In Biotech You Should Learn Today," a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotechnology research. Before we begin, a quick shot: it seems that Acorda Therapeutics (ACOR) is recovering a signi...
Source: SeekingAlpha
Date: November, 21 2017 08:00
Your Daily Pharma Scoop: Valeant Remains Risky, Novartis's Kisqali, Tesaro Tumbles
This abridged “Daily Scoop” is published by Avisol Capital Partners, which runs the physician-managed Total Pharma Tracker healthcare investment research service on Seeking Alpha Marketplace. Analysis of top Seeking Alpha coverage: Valeant Today we will disc...
Source: SeekingAlpha
Date: November, 09 2017 08:23

 


About Astellas Pharma, Inc. (OTC: ALPMF)

Logo for Astellas Pharma, Inc. (OTC: ALPMF)

Not available

 

Contact Information

 

 

Current Management

  • Masao Yoshida / CEO, President

Current Share Structure

  • Market Cap: $7,206,654,840 - 05/11/2018
  • Issue and Outstanding: 467,964,600 - 11/30/2011

 


Recent Filings from (OTC: ALPMF)

Filing to become effective immediately upon filing
Filing Type: F-6EFFiling Source: edgar
Filing Date: December, 21 2017
Post-effective amendment to a previously filed F-6
Filing Type: F-6 POSFiling Source: edgar
Filing Date: September, 29 2017

 

 


Daily Technical Chart for (OTC: ALPMF)

Daily Technical Chart for (OTC: ALPMF)


Stay tuned for daily updates and more on (OTC: ALPMF)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (OTC: ALPMF)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

OTC Report
@OTCReporter

 

 


Disclaimer: OTC Report publishes reports providing information on selected companies. OTC Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. OTC Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in ALPMF is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. OTC Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. OTC Report does not own any shares of ALPMF and does not buy, sell, or trade any shares of ALPMF. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by OTC Report. All rights reserved. Our Full Disclaimer: http://otc.report/disclaimer/